BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AAV-NTN: Completed Phase IIb enrollment

Ceregene completed enrollment of 51 patients in the double-blind, sham-controlled Phase IIb portion of a U.S. Phase I/IIb trial evaluating CERE-120 administered via stereotactic injection directly into the...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >